Dr Guntard Gutmann
Angel Investor
Dr Guntard Gutmann is a convertible note investor focused on Health Care and Life Science. Dr Guntard Gutmann
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Dr Guntard Gutmann invests in
Stages Dr Guntard Gutmann invests in
Countries Dr Guntard Gutmann invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 1 (50%)
- Life Science 1 (50%)
- Therapeutics 1 (50%)
- Biotechnology 1 (50%)
- Pharmaceutical 1 (50%)
Stage
- Convertible Note 1 (50%)
- Venture - Series Unknown 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
HMNC Brain Health
|
HMNC Brain Health develops patented genetic tests and combines those with innovative exclusively in-licensed medications, resulting in precise therapies for depression and other neuropsychiatric disorders.Founded in 2010, the privately held biotech company combines the development of machine learning-enabled companion diagnostics with specifictherapeutics to personalize the treatment of neuropsychiatric disorders with a focus on depression. The ultimate goal is to improve the lives of patients by developing highly disruptive solutions for their high unmet medical needs. HMNC Brain Health strives to reduce not only the immense individual burden but also the societal impact of these diseases. | $14.3M / Venture - Series Unknown / Oct 20, 2022 | |
|
HMNC Brain Health
|
HMNC Brain Health develops patented genetic tests and combines those with innovative exclusively in-licensed medications, resulting in precise therapies for depression and other neuropsychiatric disorders.Founded in 2010, the privately held biotech company combines the development of machine learning-enabled companion diagnostics with specifictherapeutics to personalize the treatment of neuropsychiatric disorders with a focus on depression. The ultimate goal is to improve the lives of patients by developing highly disruptive solutions for their high unmet medical needs. HMNC Brain Health strives to reduce not only the immense individual burden but also the societal impact of these diseases. | $10.7M / Convertible Note / Aug 03, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Featured in Investor Lists
Recommended lists
FAQ
What does Dr Guntard Gutmann invest in?
Dr Guntard Gutmann invests primarily in Health Care, Life Science and Therapeutics startups, most often at Convertible Note and Venture - Series Unknown stage. Most of the 2 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Dr Guntard Gutmann?
Public channels for Dr Guntard Gutmann include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Dr Guntard Gutmann last invest?
The most recent investment recorded for Dr Guntard Gutmann closed in Oct 2022. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
